In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y

Maria Mironova; Averell H Sherker

doi:10.7326/ANNALS-24-00206-JC

In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced fibrosis at 1 y

Ann Intern Med. 2024 Jun;177(6):JC63. doi: 10.7326/ANNALS-24-00206-JC. Epub 2024 Jun 4.

Authors

Maria Mironova¹, Averell H Sherker²

Affiliations

¹ Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA (M.M.).
² Liver Diseases Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Maryland, USA (A.H.S.).

PMID: 38830210
DOI: 10.7326/ANNALS-24-00206-JC

Abstract

Harrison SA, Bedossa P, Guy CD, et al. MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509. 38324483.

Publication types

Comment

MeSH terms

Clinical Trials, Phase III as Topic
Humans
Liver Cirrhosis* / complications
Male
Non-alcoholic Fatty Liver Disease* / complications
Non-alcoholic Fatty Liver Disease* / drug therapy
Randomized Controlled Trials as Topic